China Resources Pharmaceutical Group Announces Major Acquisition of Lier Chemical Shares
Key Points of the Acquisition
- Significant Share Acquisition: On 29 July 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma, Stock Code: 3320), entered into a Share Purchase Agreement to acquire an aggregate of 188,102,749 shares of Lier Chemical Group Co., Ltd. (Lier Chemical, SZSE: 002258), representing approximately 23.50% of Lier Chemical’s equity.
- Transaction Value: The proposed consideration is RMB 30.07 per share, totaling RMB 5,656,249,662.43. This makes CR Double-Crane the largest shareholder in Lier Chemical, which will become a non-wholly-owned subsidiary of CR Pharma.
- Vendors: The shares are being acquired from Sichuan Jiuyuan Investment Holdings Group Co., Ltd. (Jiuyuan Group) and Sichuan Huacai Technology Co., Ltd. (Huacai Technology), both ultimately owned by the China Academy of Engineering Physics.
- Completion Conditions: The deal is subject to several conditions, including internal approvals, state-owned asset supervision approval, merger control filings, and payment of deposits. If not fulfilled within 120 days, the agreement will be terminated.
- Payment Arrangements: CR Double-Crane is to pay a 30% contract deposit (RMB 1.44 billion to Jiuyuan Group and RMB 252.7 million to Huacai Technology, less previously paid application deposits), which will be converted into the consideration upon completion. The entire transaction will be settled in cash, funded by CR Double-Crane’s own or self-raised funds.
- Listing Rule Implications: The transaction is classified as a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules (exceeds 5% but less than 25% of relevant percentage ratios), requiring notification and announcement but not shareholders’ approval.
Strategic and Financial Rationale
- Accelerating Synthetic Biology Expansion: CR Pharma is actively developing its synthetic biology business, identified as a key growth area in CR Double-Crane’s 15th Five-Year strategic plan. The acquisition offers a shortcut to industrialisation of synthetic biology products by leveraging Lier Chemical’s established industrial production platform.
- Lier Chemical’s Capabilities: Lier Chemical is China’s largest producer of chloropyridine-based pesticide ingredients and a major producer of glufosinate-ammonium. It operates seven production bases, covering the full industrial chain from raw materials to final formulations, and has developed a synthetic biology manufacturing platform.
- Synergies: CR Double-Crane will be able to commercialise its pipeline of synthetic biology products using Lier Chemical’s infrastructure, while Lier Chemical can leverage CR Double-Crane’s technology and management, enhancing competitiveness and market position for both groups.
Financial Details of Lier Chemical
- 2024 Revenue: RMB 7.31 billion
- 2025 Revenue: RMB 9.01 billion
- Q1 2026 Revenue: RMB 2.31 billion
- 2025 Net Profit: RMB 580.7 million
- Q1 2026 Net Profit: RMB 136.3 million
- Total assets as of Q1 2026: RMB 16.78 billion
- Net assets as of Q1 2026: RMB 9.39 billion
Key Shareholder and Investor Considerations
- Potential Share Price Impact: As this acquisition positions CR Pharma as the largest shareholder in a leading chemical and biotechnology company, it could significantly impact CR Pharma’s future earnings, strategic positioning, and share valuation.
- Deal Uncertainty: Completion is subject to multiple regulatory and internal approvals. There is risk the deal may not proceed if conditions are not satisfied within the stipulated period.
- Transitional Protections: During the transitional period, the vendors have committed not to take actions that would materially affect Lier Chemical’s value, operations, or management without CR Double-Crane’s written consent.
- Termination Clauses: The agreement can be terminated if PRC laws, court judgments, or regulatory actions prohibit the acquisition, or by mutual consent.
- Reputational and Regulatory Factors: The deal involves state-owned assets and major PRC institutions, which may draw regulatory and market attention.
Board and Management
The Board of China Resources Pharmaceutical Group Limited is chaired by Mr. Bai Xiaosong, with a mix of executive, non-executive, and independent non-executive directors.
Disclaimer
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisers before making investment decisions. The transaction described is subject to regulatory and other approvals and may not proceed as described. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.
華潤醫藥集團公布重大收購利爾化學股份詳情
收購重點
- 重大股份收購：2026年7月29日，華潤雙鶴藥業股份有限公司（華潤雙鶴，華潤醫藥集團之子公司）與四川久遠投資控股集團有限公司及四川化材科技有限公司簽訂股份買賣協議，收購利爾化學股份有限公司（利爾化學，深交所：002258）總共188,102,749股，佔約23.5%權益。
- 交易金額：每股作價人民幣30.07元，總交易金額達人民幣56.56億元，華潤雙鶴將成為利爾化學最大股東，利爾化學亦將成為華潤醫藥之非全資子公司。
- 賣方背景：股份來自久遠集團及化材科技，兩者最終控股方均為中國工程物理研究院。
- 完成條件：協議需獲多項條件滿足，包括內部審批、國資監管部門批准、競爭審查及定金支付，如120天內未達成則協議終止。
- 支付安排：華潤雙鶴需支付總作價30%作為合同定金（久遠集團收人民幣14.44億元，化材科技收2.53億元，扣除已繳申請定金），待完成時自動轉為交易對價，全以現金支付，資金來源為自有或自籌資金。
- 上市規則影響：本次交易屬披露交易（涉及比例超5%但低於25%），需作公告但毋須股東大會批准。
戰略及財務考慮
- 推動合成生物學業務：華潤醫藥積極拓展合成生物學領域，此收購有助於利用利爾化學現有產業化平台，加速合成生物產品的產業化進程。
- 利爾化學實力：利爾化學為國內最大氯吡啶類農藥原藥生產商，亦是草銨膦及草銨膦-P主要生產商，擁有七大生產基地，覆蓋原料至製劑的完整產業鏈，並已建立合成生物製造平台。
- 協同效應：華潤雙鶴可利用利爾化學成熟平台進行產品商業化，利爾化學亦可借助華潤雙鶴技術及管理提升市場競爭力，雙方實現業務協同。
利爾化學財務詳細
- 2024年收入：人民幣73.1億元
- 2025年收入：人民幣90.1億元
- 2026年第一季收入：人民幣23.1億元
- 2025年淨利潤：人民幣5.81億元
- 2026年第一季淨利潤：人民幣1.36億元
- 2026年第一季總資產：人民幣167.8億元
- 2026年第一季淨資產：人民幣93.9億元
股東及投資者須知
- 潛在股價影響：作為戰略性產業整合，本次收購將提升華潤醫藥盈利能力及行業地位，對公司未來價值有潛在重大影響。
- 交易不確定性：交易尚需多項審批，若未能於規定時間內完成條件，則交易或告吹。
- 過渡期保護：過渡期內賣方承諾不會擅自更改利爾化學重大事項，保障公司價值及運營。
- 終止條款：若中國法律、法院判決或監管禁止本次收購或雙方同意，協議可終止。
- 國資及監管因素：涉及國有資產和重要科研院所，市場及監管關注度高。
董事會及管理層
華潤醫藥董事局由白曉松先生擔任主席及執行董事，並有多名執行、非執行及獨立非執行董事組成。
免責聲明
免責聲明：本文僅供參考，並不構成任何投資建議。投資者應自行審慎分析並諮詢專業人士後才作出投資決定。上述交易尚需監管及其他批准，未必如期完成。股東及潛在投資者買賣本公司證券時應保持審慎。
